NMD Pharma discovers and develops novel therapeutics for neuromuscular diseases, focusing on small molecule inhibitors of skeletal muscle-specific ClC-1 ion channels
NMD Pharma discovers and develops novel therapeutics for neuromuscular diseases, focusing on small molecule inhibitors of skeletal muscle-specific ClC-1 ion channels. Their lead candidate is in clinical development for conditions like Charcot-Marie-Tooth disease, myasthenia gravis, and spinal muscular atrophy.